DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 8.89

Change

+0.06 (+0.68)%

Market Cap

USD 0.17B

Volume

9.82K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.80 (+0.78%)

USD 16.82B
IVV:AU iShares Core S&P 500 AUD

+0.20 (+0.34%)

USD 8.73B
VGS:AU Vanguard MSCI International Sh..

+0.56 (+0.43%)

USD 8.59B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.35 (+0.63%)

USD 6.70B
IOZ:AU Ishares Core S&P/Asx 200

+0.24 (+0.72%)

USD 6.23B
STW:AU SPDR® S&P/ASX 200 Fund

+0.56 (+0.75%)

USD 5.58B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.24 (+0.59%)

USD 4.86B
NDQ:AU Betashares Nasdaq 100

+0.19 (+0.42%)

USD 4.83B
A200:AU BetaShares Australia 200

+1.16 (+0.84%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

+1.32 (+0.31%)

USD 4.67B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.25% 60% D- 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.25% 61% D- 56% F
Trailing 12 Months  
Capital Gain 16.36% 48% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.36% 49% F 53% F
Trailing 5 Years  
Capital Gain 49.41% 81% B- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.41% 81% B- 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 6.94% 78% C+ 57% F
Dividend Return 8.50% 73% C 55% F
Total Return 1.56% 52% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 8.40% 63% D 93% A
Risk Adjusted Return 101.19% 96% N/A 98% N/A
Market Capitalization 0.17B 34% F 65% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.